159 related articles for article (PubMed ID: 33857884)
1. Reflection: burden of cervical cancer in Sub-Saharan Africa and progress with HPV vaccination.
Ngcobo N; Jaca A; Iwu-Jaja CJ; Mavundza E
Curr Opin Immunol; 2021 Aug; 71():21-26. PubMed ID: 33857884
[TBL] [Abstract][Full Text] [Related]
2. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
3. Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review.
Perlman S; Wamai RG; Bain PA; Welty T; Welty E; Ogembo JG
PLoS One; 2014; 9(3):e90912. PubMed ID: 24618636
[TBL] [Abstract][Full Text] [Related]
4. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
5. The burden of human papillomavirus infections and related diseases in sub-saharan Africa.
De Vuyst H; Alemany L; Lacey C; Chibwesha CJ; Sahasrabuddhe V; Banura C; Denny L; Parham GP
Vaccine; 2013 Dec; 31 Suppl 5(0 5):F32-46. PubMed ID: 24331746
[TBL] [Abstract][Full Text] [Related]
6. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease.
Mboumba Bouassa RS; Prazuck T; Lethu T; Jenabian MA; Meye JF; Bélec L
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):613-627. PubMed ID: 28440679
[TBL] [Abstract][Full Text] [Related]
8. Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services?
Amponsah-Dacosta E; Blose N; Nkwinika VV; Chepkurui V
Front Public Health; 2022; 10():799984. PubMed ID: 35174123
[TBL] [Abstract][Full Text] [Related]
9. Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: a modeling-based approach.
Tracy JK; Schluterman NH; Greene C; Sow SO; Gaff HD
Vaccine; 2014 May; 32(26):3316-22. PubMed ID: 24731734
[TBL] [Abstract][Full Text] [Related]
10. Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review.
Kutz JM; Rausche P; Gheit T; Puradiredja DI; Fusco D
BMC Public Health; 2023 May; 23(1):974. PubMed ID: 37237329
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccination uptake and determinant factors among adolescent schoolgirls in sub-Saharan Africa: A systematic review and meta-analysis.
Asgedom YS; Kebede TM; Seifu BL; Mare KU; Asmare ZA; Asebe HA; Kase BF; Shibeshi AH; Tebeje TM; Sabo KG; Fente BM; Lombebo AA; Koyira MM; Kassie GA
Hum Vaccin Immunother; 2024 Dec; 20(1):2326295. PubMed ID: 38505959
[TBL] [Abstract][Full Text] [Related]
12. No Vacillation on HPV Vaccination.
Sipp D; Frazer IH; Rasko JEJ
Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
[TBL] [Abstract][Full Text] [Related]
13. Prevention of human papillomavirus (HPV) infection and cervical cancer in China: how does HPV vaccination bring about benefits to Chinese women?
Liu X; Feng A; Cui Y; Tobe RG
Biosci Trends; 2013 Aug; 7(4):159-67. PubMed ID: 24056165
[TBL] [Abstract][Full Text] [Related]
14. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Cervical Cancer in Sub-Saharan Africa: The Advantages and Challenges of HPV Vaccination.
Black E; Richmond R
Vaccines (Basel); 2018 Sep; 6(3):. PubMed ID: 30205561
[TBL] [Abstract][Full Text] [Related]
17. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda.
Ngcobo NJ; Burnett RJ; Cooper S; Wiysonge CS
S Afr Med J; 2018 Dec; 109(1):13-15. PubMed ID: 30606297
[TBL] [Abstract][Full Text] [Related]
19. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer in sub-Saharan Africa: an urgent call for improving accessibility and use of preventive services.
Dzinamarira T; Moyo E; Dzobo M; Mbunge E; Murewanhema G
Int J Gynecol Cancer; 2023 Apr; 33(4):592-597. PubMed ID: 36368710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
